Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S Finn, Masafumi Ikeda, Andrew X Zhu, Max W Sung, Ari D Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Konstantin Mamontov, Tim Meyer, Tomoki Kubota, Corina E Dutcus, Kenichi Saito, Abby B Siegel, Leonid Dubrovsky, Kalgi Mody, Josep M Llovet, Richard S Finn, Masafumi Ikeda, Andrew X Zhu, Max W Sung, Ari D Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Konstantin Mamontov, Tim Meyer, Tomoki Kubota, Corina E Dutcus, Kenichi Saito, Abby B Siegel, Leonid Dubrovsky, Kalgi Mody, Josep M Llovet

Abstract

Purpose: The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study of lenvatinib plus pembrolizumab (an anti-PD-1 antibody) in unresectable HCC (uHCC).

Patients and methods: In this open-label multicenter study, patients with uHCC received lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily and pembrolizumab 200 mg intravenously on day 1 of a 21-day cycle. The study included a dose-limiting toxicity (DLT) phase and an expansion phase (first-line patients). Primary objectives were safety/tolerability (DLT phase), and objective response rate (ORR) and duration of response (DOR) by modified RECIST (mRECIST) and RECIST version 1.1 (v1.1) per independent imaging review (IIR; expansion phase).

Results: A total of 104 patients were enrolled. No DLTs were reported (n = 6) in the DLT phase; 100 patients (expansion phase; included n = 2 from DLT phase) had received no prior systemic therapy and had Barcelona Clinic Liver Cancer stage B (n = 29) or C disease (n = 71). At data cutoff, 37% of patients remained on treatment. Median duration of follow-up was 10.6 months (95% CI, 9.2 to 11.5 months). Confirmed ORRs by IIR were 46.0% (95% CI, 36.0% to 56.3%) per mRECIST and 36.0% (95% CI, 26.6% to 46.2%) per RECIST v1.1. Median DORs by IIR were 8.6 months (95% CI, 6.9 months to not estimable [NE]) per mRECIST and 12.6 months (95% CI, 6.9 months to NE) per RECIST v1.1. Median progression-free survival by IIR was 9.3 months per mRECIST and 8.6 months per RECIST v1.1. Median overall survival was 22 months. Grade ≥ 3 treatment-related adverse events occurred in 67% (grade 5, 3%) of patients. No new safety signals were identified.

Conclusion: Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC. Toxicities were manageable, with no unexpected safety signals.

Trial registration: ClinicalTrials.gov NCT03006926.

Figures

FIG 1.
FIG 1.
Kaplan-Meier estimates of (A) progression-free survival (PFS) by modified RECIST per independent imaging review (IIR), (B) PFS by RECIST version 1.1 per IIR, and (C) overall survival (OS; efficacy analysis set). NE, not estimable.
FIG 2.
FIG 2.
Percentage change from baseline in sums of diameters of target lesions by (A) modified RECIST (mRECIST) per independent imaging review (IIR), (B) mRECIST per investigator review, and (C) RECIST version 1.1 per IIR. CR, complete response; HCC-1L, hepatocellular carcinoma first line; NE, not estimable; PD, progressive disease; PR, partial response; SD, stable disease. (a) Unconfirmed PR. (b) Non-CR/non-PD. (c) No. of patients with both baseline and postbaseline sums of diameters of target lesions.
FIG 3.
FIG 3.
Percentage change from baseline in sums of diameters of target lesions by (A) modified RECIST per independent imaging review (IIR) and (B) RECIST version 1.1 per IIR. (a) Value (127.8%) beyond y-axis limit is truncated and not displayed.
FIG A1.
FIG A1.
Kaplan-Meier estimate of duration of response by (A) modified RECIST and (B) RECIST version 1.1 per independent imaging review. NE, not estimable.
FIG A2.
FIG A2.
Duration of treatment and response assessments by (A) modified RECIST and (B) RECIST version 1.1 per independent imaging review. BOR, best overall response; CR, complete response; DLT, dose-limiting toxicity; EXP, expansion; NE, not estimable; PD, progressive disease; PR, partial response; SD, stable disease. (a) Non-CR/non-PD. (b) Unconfirmed PR.
FIG A3.
FIG A3.
Kaplan-Meier estimate of time to progression (TTP) by (A) modified RECIST and (B) RECIST version 1.1 per independent imaging review.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
    1. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.
    1. Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599–616.
    1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
    1. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
    1. Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14:5459–5465.
    1. Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664–671.
    1. Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340:97–103.
    1. Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.
    1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.
    1. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
    1. Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681–700.
    1. Ringelhan M, Pfister D, O’Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222–232.
    1. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.
    1. Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ, Merck Sharp & Dohme, 2020.
    1. Opdivo (nivolumab) [package insert]. Princeton, NJ, Bristol Myers Squibb, 2020.
    1. Zhu AX, Finn RS, Edeline J, et al: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol 19:940-952, 2018 [Erratum: Lancet Oncol 19:e440, 2018]
    1. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193–202.
    1. Schmidt EV. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. Semin Immunopathol. 2019;41:21–30.
    1. 2020;38:2981–2992. Makker V, Taylor MH, Aghajanian C, et al: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol.
    1. Yervoy (ipilimumab) [package insert]. Princeton, NJ, Bristol Myers Squibb, 2020.
    1. Lenvima (lenvatinib) [package insert]. Woodcliff Lake, NJ, Eisai, 2020.
    1. Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325–340.
    1. Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14:e0212513.
    1. Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109:3993–4002.
    1. Jiang JF, Lao YC, Yuan BH, et al. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: Advances and challenges. Oncotarget. 2017;8:33911–33921.
    1. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346.
    1. Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: Looking outside the box. J Hepatol. 2020;72:342–352.
    1. Yau T, Park JW, Finn RS, et al: CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 30:v874-v875, 2019 (suppl 5; abstr LBA38 PR)
    1. Finn RS, Qin S, Ikeda M, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894-1905, 2020.
    1. Reference deleted.
    1. National Comprehensive Cancer Network: NCCN Guidelines: Hepatobiliary cancers—Version 1.2020. .
    1. Yau T, Kang Y-K, Kim T-Y, et al: Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. J Clin Oncol 37, 2019 (suppl; abstr 4012)
    1. Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52:512–519.
    1. Finn RS, Kudo M, Cheng A-L, et al: Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT] [abstract]. Ann Oncol 29:viii17-viii18, 2018 (suppl 8; abstr 59PD)
    1. Melero I, Neely J, Sangro B, et al: Biomarkers and clinical outcomes in nivolumab-treated patients with advanced hepatocellularcarcinoma in CheckMate 040. Ann Oncol 30:vi106, 2019 (suppl; abstr MO2-11-1[Encore])

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir